501 related articles for article (PubMed ID: 34196077)
1. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
[TBL] [Abstract][Full Text] [Related]
2. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
6. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
7. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
[TBL] [Abstract][Full Text] [Related]
10. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
[TBL] [Abstract][Full Text] [Related]
11. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Front Cell Dev Biol; 2022; 10():851032. PubMed ID: 35433707
[TBL] [Abstract][Full Text] [Related]
13. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
14. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
15. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
18. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
